Andrew Hill Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.57M Buy
13,232
+1,277
+11% +$566K 4.88% 3
2026
Q1
$5.34M Sell
11,955
-453
-4% -$211K 4.76% 2
2025
Q4
$5.63M Buy
12,408
+8,699
+235% +$3.75M 4.28% 9
2025
Q3
$1.45M Sell
3,709
-4,294
-54% -$1.79M 1.13% 26
2025
Q2
$3.56M Buy
8,003
+1,430
+22% +$659K 2.87% 17
2025
Q1
$3.19M Buy
6,573
+19
+0.3% +$8.85K 3.08% 14
2024
Q4
$2.64M Sell
6,554
-2,335
-26% -$1.08M 1.96% 22
2024
Q3
$4.13M Sell
8,889
-65
-0.7% -$31.2K 3.1% 14
2024
Q2
$4.2M Buy
8,954
+32
+0.4% +$13.9K 3.48% 10
2024
Q1
$3.73M Sell
8,922
-3,340
-27% -$1.41M 3.29% 8
2023
Q4
$4.99M Buy
+12,262
New +$4.53M 5.2% 2
2022
Q3
$4.38M Buy
+15,138
New +$4.36M 5.95% 4

Other funds holding VRTX

Andrew Hill Investment Advisors's VRTX Position: Q2 2026 in Review

Andrew Hill Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $566K and bringing the position to 13,232 shares worth $6.57M. The position accounts for 4.88% of the portfolio, ranked #3.

Andrew Hill Investment Advisors first reported a position in VRTX in Q3 2022 and has held it in 12 quarters since. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Andrew Hill Investment Advisors held 13,232 shares of Vertex Pharmaceuticals worth $6.57M as of Q2 2026.
  • Andrew Hill Investment Advisors bought 1,277 Vertex Pharmaceuticals shares in Q2 2026, an estimated $566K.
  • Vertex Pharmaceuticals made up 4.88% of Andrew Hill Investment Advisors's portfolio in Q2 2026, its #3 holding.
  • Andrew Hill Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Andrew Hill Investment Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.